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PURPOSE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have shown superb
efficacy in lowing LDL-C for patients who are not controlled by or are intolerant of first line
medications such as high intensity statins and ezetimibe. Yet because of their high yearly cost of
over $14,000 along with life-long cumulative costs, insurance payers have created strict
guidelines to control utilization. This is an important area of research because there are no large
retrospective studies that have examined the differences in utilization uptake of PCSK9
inhibitors among the major payer categories. The purpose of this study is to establish whether
insurance coverage payer type affects the rate of utilization uptake of PCSK9 inhibitors.

METHODS: Prescription billing data for PCSK9 inhibitor for commercially insured patients,
Medicare beneficiaries with supplemental insurance, and Medicaid patients were extracted from
Truven Health Analytics MarketScan® data for 2015. A patient cohort defined by atorvastatin 80
mg or rosuvastatin 40 mg utilization (maximum dose high intensity statins) served as the
denominator population for uptake rate calculations. Data were limited to the first 6-months post
FDA approval of PCSK9 inhibitors. PCSK9 inhibitor uptake rates were estimated using simple
projection and regression modeling. Out-of-pocket costs were estimated by insurance type.

RESULTS: The results of the claims ratio analysis indicate that the three insurance payer
cohorts had significantly different uptake ratios (P<0.0001) at six months. Initially, the Private
insurance cohort had a faster uptake ratio, but the Medicare cohort ratio surpassed the Private
insurance growth rate by the end of the study. Furthermore, the two forecasting growth curves
(percent increase and ordinary least squares regression) indicate that Medicare has the greater
anticipated future uptake utilization when compared to the Private insurance payer. Using
regression modeling, the uptake slope showed a trend towards greater uptake for Medicare
compared with commercially insured subjects (p=0.0772). Importantly, PCSK9 inhibitor uptake
for the Medicaid cohort was much smaller compared to the commercially insured and Medicare
cohorts.

CONCLUSION: The analysis of PCSK9 inhibitor claims during the first 6 months post FDA
approval revealed a slightly faster uptake trend in Medicare patients compared with patients with
commercial insurance, with uptake for Medicaid patient being much lower. The results indicate
that barriers to access to PCSK9 inhibitors may vary by insurance. Future studies should
examine if barriers are associated with: 1) stricter approval guidelines to manage PCSK9
inhibitor utilization by some insurers; or 2) disparities in prescribing rates associated with
insurance type.

KEYWORDS: PCSK9 Inhibitors, Evolocumab, Alirocumab, Cardiovascular Disease, LDL
Cholesterol, DHA, Doctor of Health Administration.
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CHAPTER 1
INTRODUCTION

Background of PCSK9 Inhibitors and Need for Analysis
Uncontrolled hyperlipidemia represents a significant risk factor for the development of
clinical atherosclerotic cardiovascular disease (ASCVD) and remains one of the leading causes
of death globally (Benjamin et al., 2017; Jernberg et al., 2015). 73.5 million Adults (31.7%) in
the United States have low-density lipoprotein (LDL) above target goals. More importantly, only
less than half (48.1%) are getting treatment to lower their LDL-C levels with many who are
being treated unable to reach their target LDL-C levels (Benjamin et al., 2017; Centers for
Disease Control and Prevention (CDC), 2016; Mozaffarian et al., 2015).
High intensity HMG-CoA reductase inhibitors such as atorvastatin 40 or 80 mg and
rosuvastatin 20 or 40 mg have remained the first-line treatment for patients with high cholesterol
levels according to the 2013 American College of Cardiology/American Heart Association
guidelines (Graham, Catapano, & Wong, 2017). Otherwise known as statin medications, they are
the treatment of choice for both primary as well as secondary prevention of ASCVD and are
available as low cost generic medications. (Graham et al., 2017; Nayor & Vasan, 2016). Statins
have shown clinical efficacy in reducing ASCVD incidence by lowering lipoprotein cholesterol
(LDL-C) levels (Mihaylova et al., 2012). However, there are patients for whom statin lipid
lowering therapies do not work, and they continue to have elevated LDL-C levels. Primary
reasons for statin therapy failure include an inherited condition called familial
hypercholesterolemia (FH) which depending on the type of defect can result in highly elevated
LDL-C levels and unsatisfactory response to statin therapy. There are two types of FH including
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homozygous FH (HoFH) and heterozygous FH (HeFH). Secondly, there are patients who are
unable to tolerate statin therapy at treatment doses due to the development of intolerable adverse
effects. The occurrence of these very rare adverse events can be very serious, resulting in
significant muscle pain up to life threatening rhabdomyolysis and severely elevated creative
kinase levels leading to renal failure and dialysis. There are also other effects including risk of
new onset diabetes as well as severely elevated liver transaminases (Katz, Intwala, & Stone,
2014).
A new class of medications called proportion convertase subtilizing/nexin type 9
inhibitors (PCSK9 inhibitors) was recently approved by the Food and Drug Administration
(FDA). These medications have the potential of significant utilization, but also have very high
economic costs. The two PCSK9 inhibitors currently on the market are alirocumab (Praluent)
approved in July 2015 (Regeneron, 2017) and evolocumab (Repatha) approved in August 2015
(Amgen, 2017). They are classified as specialty medications because they are injectable
biological medications and have high monetary costs. PCSK9 inhibitors have demonstrated
significant efficacy in dramatically lowering LDL-C for patients not controlled by high intensity
statins and ezetimibe.
PCSK9 inhibitors reduce the levels of PCSK9 protein circulating in the body, which
regulates the LDL-C levels in the bloodstream by breaking down the LDL receptors that remove
LDL-C from the blood (see figure 1). The inhibition of the PCSK9 protein results in more LDL
receptors becoming available to remove LDL-C from the circulating blood, resulting in lower
levels of LDL-C. The reduction of circulating LDL-C in the blood is believed to lower a
patient’s risk for developing cardiac atherosclerotic complications. Clinical studies for FDA
approval have shown PCSK9 inhibitors to be safe and effective in reducing LDL-C levels. When
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added to statin therapy, PCSK9 inhibitors reduce LDL-C levels by an additional 50 to 60 percent
(Melendez, Krishnaji, Wooten, & Lopez, 2017; Robinson et al., 2015; Sabatine et al., 2015).
Results from large clinical trials are expected in the near future (2018/2019); those results are
expected to clarify whether there are any significant clinical reductions in heart attack risk and
mortality when using these new therapies. The FOURIER study showing composite cardiac risk
reduction was published in May 2017 (Sabatine et al., 2017) and the ODYSSEY study will be
presented in March 2018. These medications have very few drug interactions and the most
commonly reported adverse effects in clinical trials were injection site reactions, muscle pain,
upper respiratory tract infection, back pain, and headache (Robinson et al., 2015; Sabatine et al.,
2015). Both medications are available in once or twice monthly self-injectable dosage forms,
with cardiologists, lipid specialists, and endocrinologists anticipated to be the top prescribers of
these medications.
While PCSK9 inhibitors have an important role in filling an unmet need in patients
unable to reach their LDL-C goal, the yearly cost of these medications, which can be upwards of
$14,000, remains highly controversial (Fonarow et al., 2017). Once therapy is initiated, patients
will potentially require lifelong maintenance therapy of PCSK9 inhibitors to continue to achieve
clinical results, leading to high cumulative medication costs. Furthermore, the accelerated FDA
approval process focused primarily on medication side effect profile (safety) and LDL-C
lowering ability rather than whether the medication had long-term clinical efficacy in reducing
the incidence of ASCVD and mortality. Because of these factors, insurance payers have created
coverage guidelines to manage utilization and costs aggressively; those guidelines may even be
more stringent than the FDA approved indications. Most approval guidelines only allow
coverage of a PCSK9 inhibitor for secondary prevention of ASCVD; i.e., patients need
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documentation of a coronary event related to atherosclerosis or coronary revascularization
procedure for coverage to occur. Additionally, many insurance companies require documentation
of treatment failure or intolerance of at least two high intensity statins such as atorvastatin and
rosuvastatin prior to covering PCSK9 inhibitors, while other insurers even require the addition of
ezetimibe to high intensity statin therapy. If ongoing clinical outcome trials are positive for a
reduction in cardiac events and mortality, there will be an anticipated increase in utilization for
the primary prevention of ASCVD in patients with high LDL-C level who currently have low to
moderate cardiovascular risk factors (Hadjiphilippou & Ray, 2017).
Another method that insurance payers have used to manage utilization is to increase the
patient’s cost sharing by placing PCSK9 inhibitors in higher coverage tiers; this results in larger
copayments, thus decreasing medication access by making the drugs unaffordable for many
patients (Doshi, Li, Ladage, Pettit, & Taylor, 2016). Significant cost sharing is built into
Medicare plans to promote value and cost appreciation among providers and patients;
medications are prescribed with an overall goal of limiting drug cost expenditures. PCSK9
inhibitors are commonly on the specialty tier 5 level of Medicare prescription plans, which
results in copayments of up to 45% of the medication costs if coverage is approved by the
Medicare insurance carriers. Based on the cost of these medications, copayments range typically
between $500 - $600 per month for Medicare patients in the “coverage gap” phase prior to
reaching the “catastrophic” phase when copayments are reduced to 5% of the medication costs.
These high copayment costs make it very difficult for Medicare patients to afford the
medications. There are patient assistance programs, but these programs are often closed to new
enrollment due to lack of funding. A second goal of the cost sharing and tier levels is to
indirectly promote price competition between pharmaceutical companies in order to lower costs
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(Gautam & Pan, 2016; Lotvin, Shrank, Singh, Falit, & Brennan, 2014; Reinhardt, 2015). The
indirect nature of the price competition is very important because Federal law specified in the
Social Security act prohibits the Secretary of Health and Human Services from being involved in
negotiating drug prices between the Medicare Part D plan sponsor and the pharmaceutical
manufacturer. Interestingly, both alirocumab and evolocumab have almost identical medication
costs and therefore have little to no competitive pressure to reduce their costs.
Differences in approval criteria between the insurance payer types (Private, Medicare
Advantage, and Medicaid) and differences in copayment costs may lead to variations in the rate
of utilization uptake of PCSK9 inhibitors among patients depending on the type of insurance.
This is an interesting area of research to show how patient access to medication treatments is
affected by approval criteria instituted by insurance payers.

Problem Statement
This study investigated the utilization uptake of PCSK9 inhibitors using prescription
claims data to highlight any differences in uptake between the three primary insurance payer
types in providing benefit coverage. The primary insurance types included Privately insured,
Medicare Advantage, and Medicaid payers. This is an important area of research because there
are only limited studies examining the differences in patient utilization uptake of PCSK9
inhibitors depending on the type of insurance provided to the patient. Literature articles indicate
that the utilization of PCSK9 inhibitors has been relatively low, which may be due to their high
cumulative costs as well as the lack of long-term clinical efficacy data regarding reducing
mortality (Fonarow et al., 2017). Additionally, there are less expensive generic medications such
as statins that can effectively decrease LDL-C to the target range in most patients.
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Research Question
Does insurance coverage type and manufacturer copayment card availability affect the rate of
utilization uptake of PCSK9 inhibitors?

Population
Archival data analysis of Privately insured, Medicare Advantage, and Medicaid PCSK9
inhibitor cohorts defined by atorvastatin 80 mg and rosuvastatin 40 mg utilization (maximum
dose high intensity statins) obtained from the Truven Health Analytics – MarketScan® Research
claims dataset during a 6-month time period from July 1, 2015 to December 31, 2015.

Assumptions
An important difference between Private insurance and government sponsored plans such
as Medicare Advantage is that manufacturer copayment cards cannot be used to cover the hefty
Medicare copayment costs due to federal anti-kickback laws. This creates a financial
predicament for Medicare patients because they will have to pay higher copayments to receive
the medication, while Private insurance plans allow for manufacturer sponsored copayment cards
to reduce out of pocket costs to $5 or less (Lotvin et al., 2014; Starner et al., 2014).
The Federal anti-kickback statute (42 U.S.C. 1320a–7b) was first written into the Social
Security amendment of 1972 to protect patients and Federal health care sponsored plans from
fraud, waste, and abuse. This statute stipulates that it is a criminal offence when a willful and
intentional payment is made to influence the selection of items or services in a health program
run by the Federal government. Violations of the anti-kickback statute can result in being
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convicted of a felony and are punishable by a fine of $25,000 and up to 5 years in prison.
Essentially, copayment cards offered by the pharmaceutical manufacturer can influence the
selection of a more expensive medication over other less expensive generic medication options.
Even though manufacturer co-pay cards are prohibited for use in Medicare Part D plans,
the Federal government allows pharmaceutical manufacturers to donate to patient assistance
programs (PAP) as “independent” charities. Examples include the Patient Access Foundation or
the Healthwell foundation set up specifically to benefit patients of Medicare Part D
("Supplemental special advisory bulletin: Independent charity patient assistance programs ").
These programs qualify patients for assistance based on their income level, with qualifications
being broad; most are limited to 400% of the Federal poverty level. There is a two-step process
with the patient assistance programs where the manufacturer donates money as a tax-deductible
contribution and then the PAP qualifies the patient eligibility based on several factors including
financial thresholds. The key premise with this type of set up is that the manufacturer does not
influence the charity on how to distribute the contributions, nor does it give the copayment
coupon directly to the patient; the presumption is that this arrangement does not unduly influence
medication selection. There are usually long waiting times to enroll patients into these programs,
because they often lack funding for new patient enrollment.
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CHAPTER 2
LITERATURE REVIEW

Specialty Pharmaceuticals
Specialty medications are large complex molecules that utilize novel approaches to
manage complex chronic diseases such as oncology, multiple sclerosis, rheumatoid arthritis, and
hepatitis C. These drugs require a complex manufacturing process, special handling through
limited distribution channels, patient education, and monitoring. The exact definition of a
specialty medication can vary depending on how the insurance payer categorizes the product, but
they are all generally classified as having high monetary costs. For example, Medicare
categorizes any medication as a specialty product if the drug cost is over $600 per month. In
addition to the high cost of these medications, they often need close follow-up due to specific
product storage as well as ongoing disease progression.
Specialty medications are causing a huge shift in the prescription drug landscape because
many of the healthcare policies and insurance benefit plans did not anticipate the current
escalation in prescription spending. For example, in the past the vast majority of prescriptions
that were filled were for low cost generic medications, as a boom in drug discoveries was
diminishing and pharmaceutical development pipelines were drying up. Blockbuster brand name
drugs like Lipitor, Prilosec, and Zocor were coming off patent, resulting in hugely
discounted generics becoming available, thus leveling off drug spending escalations.
Interestingly, this time period of high generic utilization and spending moderation was used for
establishing spending predictions and the basic framework for the Medicare Part D prescription
insurance (Doshi et al., 2016).
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Over the past decade, the advancement of new technology allowed for the discovery of
complex molecules synthesized as variants of existing biological substances already within our
bodies. These molecules work by influencing specific regulator binding sites targeting specific
disease processes. Many of these biological drug entities were developed by novel
pharmaceutical startup companies, which became very lucrative as their medications resulted in
high profit margins once approved by the FDA. In 2013, fifteen of the twenty-seven new drugs
approved by the FDA were within the specialty category, with the percentage of specialty
pharmacy approvals forecasted to increase over the next few years (Lotvin et al., 2014).
Furthermore, pharmaceutical claim costs for specialty pharmaceuticals are steadily increasing by
more than fifteen percent annually and are expected to account for more than half of all
pharmaceutical spending by 2018 ($235 billion) (Lotvin et al., 2014; Reinhardt, 2015). The
average total monthly specialty medication cost to both the insurance payer and the patient is
around $2,500 with more expensive medications costing over $30,000 per month, e.g., for the
treatment of hepatitis C (Starner et al., 2014). Reasons for the increased costs are the high
expenses in drug development as well as the complex manufacturing process. Other reasons
include manufacturers expanding their FDA approved indications, which increases the number of
total patients that would benefit from being on the medication (Shay, Louden, & Kirschenbaum,
2015). Additionally, pharmaceutical companies have set up complex limited distribution
networks for purchasing these drugs, which reduces price transparency and adds to the overall
cost of these drugs.
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Role of PCSK9 Inhibitors
The progression of ASCVD to myocardial infarction and ischemic stroke is one of the
leading global causes of death (Benjamin et al., 2017; Jernberg et al., 2015). Risk factors for
developing ASCVD include elevated systolic blood pressure, diabetes, smoking, obesity, and
increased levels of LDL-C (Benjamin et al., 2017). Reducing LDL-C has become a target of drug
therapy that utilizes statin medications to lower LDL-C and prevent the formation of
atherosclerotic plaques (Ference et al., 2017) (Ference et al., 2016) (Melendez et al., 2017).
Goals for LDL-C reduction vary based on the presence of various risk factors leading to
cardiovascular disease (Graham et al., 2017). There is significant evidence through metaanalyses showing that lowering LDL-C with statin therapy reduces the 5-year incidence of major
coronary events and revascularizations by up to 22% (Mihaylova et al., 2012). Although statins
have shown to be very useful in lowering LDL-C, many patients are not able to tolerate statins
due to their debilitating side effects such as myopathy, rhabdomyolysis, elevated hepatic
enzymes, and risk of new-onset diabetes (Katz et al., 2014). Myopathy can have a significant
impact on physical movement and quality of life often leading to discontinuation of therapy
resulting in elevated LDL-C levels and a higher risk of cardiovascular events. The incidence of
statin therapy discontinuation can affect up to 10% to 20% of patients taking statins, with a
subsequent therapy change to a second statin medication being tolerated by most patients. The
primary concern with patients who are not able to tolerate a second statin is that, up until
recently, there were no subsequent treatment options available to reduce their LDL-C and their
related cardiovascular risk (Cho et al., 2016; Vonbank et al., 2017).
While statins medications have shown good clinical efficacy in reducing mortality in
coronary artery disease (CAD), these medications have historically been associated with poor
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adherence rates. This is highly significant because treatment adherence to the medication
regimen as prescribed is an important factor in the improvement in patients’ health status. A
2002 landmark study from Canada linking medical records with statin prescription data in
elderly over two years found medication compliance rates shockingly low despite the proven
clinical effectiveness of these medications. Results indicated that only 40.1% of patients with
acute coronary syndromes were taking statins and most surprising, only 25.4% of patients taking
statins for primary prevention were still on therapy at the end of the study time period
(Jackevicius, Mamdani, & Tu, 2002). Other studies have shown similar low adherence rates
ranging from 30 to 40% which translates into a major reason for patients’ inability to reach their
LDL-C goal and prevent further cardiac events (De Vera, Bhole, Burns, & Lacaille, 2014; OforiAsenso et al., 2017; Vonbank et al., 2017). Medication non-adherence is a multifaceted issue
linked to both behavioral and system barriers resulting in patients not taking their medications as
prescribed. Typical reasons for non-adherence range from the inability to swallow pills to the
appearance of debilitating side effects such as muscle aches or even severe biological effects
including elevated liver enzymes and renal failure. Other adherence reasons include
polypharmacy as well as high medication copayment costs making medications unaffordable for
many patients (McGinnis et al., 2007). Patient-centered programs led by health professionals
who provide appropriate education, support and communication have shown to increase selfmanagement and medication adherence by continuously reinforcing the clinical importance of
taking medications as prescribed (Wouters et al., 2016). The ultimate goal of these programs is to
increase patients’ understanding of their medication therapy, prevention of progression of their
disease state, and detecting adverse drug events while assessing medication over- and underutilization. The addition of or switching to PCSK9 inhibitor therapy will still raise many of the
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same adherence to therapy concerns seen with patients taking statins, but PCSK9 inhibitor
therapies’ advantages over statins are that they have highly favorable side effect profiles similar
to placeboes as well as their once or twice monthly dosing administration.
PCKSK9 inhibitors are a new class of specialty medications that have shown superb
efficacy in decreasing LDL-C by up to 60% in patients who are not adequately controlled by
statin therapy alone (Sabatine et al., 2016). Two PCSK9 inhibitors, approved in 2015 by the
FDA, have an estimated yearly cost of over $14,000 (Fonarow et al., 2017). Both alirocumab and
evolocumab have similar indications as an adjunct to diet and maximally tolerated statin therapy
for treatment of adults with FH or ASCVD in patients who require additional lowering of LDL-C
levels. FH is an autosomal dominant genetic disorder characterized by having highly elevated
LDL-C levels in patients, which makes it highly unlikely they will reach their LDL-C goals with
statin therapy alone (Melendez et al., 2017) . On December 1, 2017, the FDA expanded
evolocumab’s approval to include an indication for stand-alone prevention of heart attacks and
strokes based on the FOURIER trial results (Sabatine et al., 2017) (Amgen, 2017).
These medications work by inhibiting the binding of the PCSK9 molecule to the LDL
receptor and their subsequent receptor degradation, which allows more LDL receptors to become
available to clear LDL-C from the bloodstream (Figure 1). Both alirocumab and evolocumab are
very well tolerated with a safety profile similar to placebo as shown by two large scale safety
studies (Hadjiphilippou & Ray, 2017). The OSLER open labeled study evaluated the long-term
safety and efficacy of evolocumab, which showed a continued significant reduction of LDL-C
and a side effect profile that was not significantly different from initial observations (Koren et
al., 2017). Similarly, the ODYSSEY LONGTERM study showed low rates of adverse reactions
with long-term use of alirocumab (Robinson et al., 2015). PCSK9 inhibitors have been shown to
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significantly reduce LDL-C levels by 50 to 60% when given in combination with statins as well
as when used as monotherapy in patients who do not tolerate statin medications. The multitude
of phase 3 studies used by the FDA for approval of alirocumab and evolocumab are presented in
further detail in Tables 1, 2, and 3. These studies analyzed PCSK9 inhibitor LDL-C reduction
efficacy in many different patient populations from FH to those with an intolerance to statin
therapy. Additional studies compared the additive LDL-C lowering effects of combining PCSK9
inhibitor therapy with either high intensity statins and ezetimibe.

Figure 1: PCSK9 Inhibitor Mechanism in the LDL-C Metabolism Pathway. A flow diagram
describing the mechanism of action of PCSK9 inhibitors (Straighthealthcare, 2017).

13

As far as clinical efficacy is concerned, the long-term effects of LDL-C lowering effects
seen with PCSK9 inhibitor therapy on cardiovascular morbidity and mortality have yet to be
fully established, as these medications were approved solely based on their dramatic ability to
lower LDL-C and safety profile (McDonagh, Peterson, Holzhammer, & Fazio, 2016). The post
FDA approval GLAGOV randomized clinical trial of 986 patients showed that the addition of
evolocumab to statin therapy resulted in a significant higher percentage of plaque regression
compared to statin plus placebo, as measured through intravascular ultrasound (Nicholls et al.,
2016). The FOURIER study (Hadjiphilippou & Ray, 2017; Sabatine et al., 2017), recently
published in May 2017 was a randomized, double-blind, placebo-controlled trial that evaluated
the benefit of adding evolocumab to statin therapy in 27,564 individuals over 2 years. Primary
endpoint results indicated that the evolocumab plus statin group had significantly fewer heart
attacks, strokes, or composite deaths compared to patients who received statin plus placebo
(9.8% vs. 11.3%, P<0.001) (Hadjiphilippou & Ray, 2017; Sabatine et al., 2017). There was a
27% reduction in risk of myocardial infarction but no reduction in cardiovascular deaths. Even
though the reduction in cardiac events was statistically significant, many clinicians and insurance
providers are skeptical in justifying the $14,000 yearly drug cost for lifelong therapy because
there was no reduction in cardiac mortality, which failed to meet the manufacturer’s predictions
on clinical efficacy (Hernandez, 2017). One of the drawbacks with this study was its relatively
short duration of two years and the potential delay of seeing the full beneficial effects of the
LDL-C lowering therapy, which may take several years to fully appreciate and comprehend.
Additionally, the seemingly small reduction in cardiac events indicates that there may be more
pathways involved in the formation of atherosclerotic plaque besides those involving the LDL-C
pathway. Most importantly, there are no stand-alone studies of the effectiveness of PCSK9 on
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cardiac event risk reduction, yet many insurance approvals are for patients who are intolerant of
statin therapy and are started on PCSK9 inhibitor monotherapy.
PCSK9 inhibitor molecules are too large to pass through the blood brain barrier, but
nonetheless, there have been concerns have been raised by researchers regarding potential side
effects of PCSK9 inhibitors, in particular, their effects on neurocognitive function despite their
significant LDL-C lowering ability (Hadjiphilippou & Ray, 2017). Furthermore, preliminary
research using a meta-analysis of the early efficacy results from the phase 2 and phase 3 trials
seems to indicate a possible link between PCSK9 inhibitor utilization and a higher rate of patient
reported cognitive adverse effects (Lipinski et al., 2016). However, a cognitive side effect
analysis of the 27,564 patients enrolled within the FOURIER study showed no significant
differences between evolocumab and placebo with respect to changes in cognitive function such
as memory deficits (Sabatine et al., 2017). Furthermore, the recent EBBINGHAUS cognitive
study (R. P. Giugliano, Mach, Zavitz, Kurtz, Im, et al., 2017), which was a randomized doubleblind placebo-controlled study involving 1974 patients, evaluated the occurrence of
neurocognitive deficits in the evolocumab group compared to the placebo group. This study was
an open label extension of the FOURIER study in which researchers followed patients over 19
months to determine whether there were any neurocognitive changes in the evolocumab
treatment group. Primary endpoints included measuring memory using the Cambridge
Neuropsychological Test Automated Battery and secondary endpoints included scores for
working memory, episodic memory, and psychomotor speed. Results indicated that there were
no significant differences in primary or secondary endpoints with respect to neurocognitive
functions (P<0.001). The authors concluded that there were no links between LDL-C levels and
neurocognitive decreases including patients who developed very low LDL-C levels (<0.65
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mmol/L) from PCSK9 inhibitor therapy. Limitations of that study included a small patient
sample size as well as a short follow-up period. A subsequent study is planned to evaluate
cognitive function in 500 patients from the FOURIER trial, which will have a duration of over 5
years (Durairaj, Sabates, Nieves, Moraes, & Baum, 2017; Robert P. Giugliano et al., 2012; R. P.
Giugliano, Mach, Zavitz, Kurtz, Im, et al., 2017; R. P. Giugliano, Mach, Zavitz, Kurtz,
Schneider, et al., 2017).
Within the next year there should be further insight on the role of PCSK9 inhibitors as the
clinicaltrials.gov website lists several ongoing investigations involving PCSK9 inhibitors to
examine their clinical effectiveness in reducing cardiac events in various patient populations
from adolescents with hypocholesteremia to adults with prior myocardial infarctions. One such
study evaluating alirocumab is the ODYSSEY OUTCOMES which is a five-year study due to be
completed in December 2017. It is anticipated that this long-term study should provide important
data on alirocumab’s clinical efficacy in reducing LDL-C levels.

Pharmacoeconomics of PCSK9 Inhibitor Therapy
PCSK9 inhibitors have created cost and benefit coverage challenges for the insurance
payers, as they have been hesitant to provide benefit coverage to PCSK9 inhibitors due to their
high potential lifelong therapy costs as well as the lack of multiple long-term trials on clinical
efficacy in preventing further cardiovascular events. The FOURIER study is the first showing
clinical effectiveness but the results were not as good as was anticipated (Hernandez, 2017).
Barriers to treatment access for patients include strict coverage ineligibility, high copayment
costs, and unavailability of patient assistance programs to cover these high copayments. In an
effort to save costs, insurance payers have created mechanisms to limit utilization by developing
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their own coverage guidelines, which may be more stringent than the FDA approved indications,
resulting in a higher likelihood that requests will be initially denied. Prior to covering PCSK9
inhibitors, all insurance plans require prior authorization approval and documentation that
medication step therapy with multiple statin therapy attempts have occurred. Medical record
documentation must include failure of, or intolerance to, at least two high intensity statins such
as atorvastatin and rosuvastatin along with a trial of ezetimibe prior to PCSK9 inhibitor coverage
in many instances. Many plans have tiered formulary levels that place specialty medications in
the highest copayment tier requiring greater patient cost sharing even if the medication is
approved (Lotvin et al., 2014) (Kesselheim, Avorn, & Sarpatwari, 2016).
With yearly costs for these medications over $14,000, many clinicians and insurance
payers have questioned their therapy cost effectiveness, high dosage cost, and contribution to
escalating US healthcare costs. Kazi et al. (2016) presented results of an initial cost effectiveness
study, which was subsequently updated after the publication of the FOURIER study evaluating
evolocumab (Kazi et al., 2016; Kazi et al., 2017). In each study, Kazi and team used the
Cardiovascular Disease Policy Model to evaluate the utilization of PCSK9 inhibitors based on
the 2015 drug acquisition cost of $14,350 per year. This simulation model is specifically useful
in predicting the incidence of coronary heart disease, stroke, and death due to non-coronary
causes in US adults aged 35 to 94 years. Outcomes were measured using lifetime major adverse
cardiovascular events (MACE), incremental quality-adjusted life year (QALY), and effect on
healthcare costs over 5 years. The investigators concluded that the addition of PCSK9 inhibitor
therapy at 2015 prices would not meet their cost effectiveness thresholds and would significantly
increase total US healthcare costs. Furthermore, they concluded that these medications are
overpriced and that a more realistic yearly price of $4,500 for PCSK9 inhibitors would be needed
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to meet their $100,000 per QALY threshold (Kazi et al., 2016). With the publication of the
FOURIER results, which showed PCSK9 inhibitor effectiveness in preventing cardiac events,
the authors reanalyzed the results of their 2016 study and found that even greater decrease in
medication costs were needed to meet their cost effectiveness thresholds (Hernandez, 2017; Kazi
et al., 2017; Mark & Schulman, 2017).
A second study looking at cost effectiveness of evolocumab using data from the
FOURIER trial calculated the cost of preventing a myocardial infarction (MI) or stroke based on
the annual cost of the evolocumab. Results indicated that it would take an additional $1.6 million
to prevent a single MI and $4.9 million to prevent a stroke. Furthermore, for evolocumab to be
cost effective, it should be priced between $4,250 and $4,500 annually. The author noted
difficulties in calculating the cost effectiveness using the FOURIER trial because this study did
not directly measure QALY, and the results, while statistically significant, did not show the
magnitude of reduction in cardiac events as had been anticipated by clinicians and researchers
(Hernandez, 2017).
A third study incorporating a Markov cohort state-transition model using the FOURIER
risk reduction results, U.S. population demographics, risk factors, event rates, and treatment
options found that evolocumab cost far exceeded their $150,000 per QALY threshold at current
medication costs. The authors concluded that to meet their threshold, the cost of the medication
needed to be substantially reduced to a yearly cost of $9,669 for the U.S. ASCVD population
with an event rate of 6.4 per 100 patient years. For the FOURIER study participants with an
annual event rate of 4.2 per 100 patient years, the evolocumab yearly cost would need to be even
further reduced to $6,780 to meet QALY thresholds. The author’s $150,000 per QALY threshold
is at the upper limit of the intermediate value care and a $100,000 per QALY used in the other
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cost effectiveness evaluations recommend reducing the medication costs even further (Fonarow
et al., 2017).
A recent poster presented at the Academy of Managed Care Pharmacy Annual Meeting in
March 2017 analyzing claims data found that there were differences in both approval rate and
approval time frame between the commercial and government payers. The investigators
reviewed 12 months of PCSK9 inhibitor claims data from the IMS Formulary Impact Analyzer
database to calculate the mean time to approval. Medicare patients were more likely to get faster
coverage approval but less likely to fill their prescription due to higher copayments when
compared to commercial payers (Baum, Rane, et al., 2017).
Evaluating the true cost of these medications is difficult and involves estimations on
complex items such as putting a dollar amount on value and the patient’s perceived benefit from
the medication. Both Amgen and Regeneron pharmaceutical companies have seemingly
incorrectly calculated the maximum cost set points they can charge while maintaining a goal of
patient easy access to benefit coverage by insurance payers. The high costs of these medications
as well as limited data on cardiovascular outcomes are resulting in significant coverage
restrictions placed on these medications by insurance payers, which makes it difficult for patients
to initiate therapy. Uptake utilization of PCSK9 inhibitors has been lower than expected; only
17% of insurance benefit authorization requests were initially approved, and only an additional
26% were approved on appeal. Primary rejection reasons included inadequate chart
documentation along with not having a trial of at least two high intensity statins at maximally
tolerated doses. A third additional requirement of adding ezetimibe therapy to statins has recently
been removed from most insurance plan criteria because ezetimibe fails to have the LDL-C
lowering ability seen with PCSK9 inhibitors. Also, after PCSK9 inhibitor therapy was approved,
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an estimated 25- 40% of patients never filled their prescriptions due to their high copayment
costs, which can be over $500 per month (Baum, Chen, & Rane, 2017; Baum, Toth, et al., 2017).
Achieving a threshold of $100,000 per QALY for cost effectiveness would necessitate reductions
in current price of more than 60% to 63% with the potential of even further reductions in an
effort to limit the escalating US healthcare costs (Mark & Schulman, 2017; Tice, Kazi, &
Pearson, 2016).

Healthcare Insurance Payers
Prescription medications have become a major contributor to the rising costs of
healthcare with increasing utilization of specialty pharmaceuticals (Kesselheim et al., 2015). The
majority of healthcare insurance plans can be divided into two broad categories: private
insurance and public (government) insurance. Private insurance is often obtained through
employers or through purchasing insurance plans through the Accountable Care Act (ACA)
Marketplace exchanges and non-government exchanges. They can be in the form of fee-forservice plans or managed care plans such as health maintenance organizations (HMOs),
preferred provider organizations (PPOs), or point of service plans (Buttorff, Andersen, Riggs, &
Alexander, 2015).
Governmental plans consist of Medicaid and Medicare. Medicaid is a state level
administered program paid by the Federal government which provides low income individuals
and their children coverage for medical and prescription expenses. Since Medicaid is a state-run
program reliant on Federal funds, the program is highly more sensitive to changes in funding
than the Private insurance payers. Furthermore, medication eligibility and coverage allowances
vary between states. Many state Medicaid programs have placed coverage restrictions in place
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for high cost medications to in an effort of save money and balance state budgets (Salzman,
2017).
The second government plan is Medicare and is administered by the Federal government.
Medicare covers people at least 65 years of age or older but also includes patients less than 65
years old with specific chronic conditions, for example, kidney failure requiring dialysis.
Medicare plans are comprised of the four individual segments listed below:


Medicare Part A: Is the hospital insurance which covers hospitalizations and nursing
rehabilitation facilities.



Medicare Part B: Is the medical insurance which covers the physician and outpatient
care such as home health and physical therapy.



Medicare Part C: Is the Medicare Advantage Plan which allows Medicare eligible
patients to enroll in a medical insurance plan similar to an HMO, PPO, or Private fee-forservice plan run by a private health insurance company (Johnson, Figueroa, Zhou, Orav,
& Jha, 2016). Part C is a bundled plan which would cover both parts A and B as well as
Part D (prescription plan) in most cases.



Medicare Part D: This is the prescription plan for Medicare and has cost sharing built in
to favor utilization of less costly generic medications. The plan was implemented in 2006
to provide universal access to prescription medications by Medicare patients. Patients that
meet low income eligibility thresholds may be eligible for the “extra help” program to
further assists in paying for prescription costs. The prescription plan can provide
coverage as a stand-along Part D plan or bundled within a Medicare Advantage (Part C)
plan.
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Medicare Advantage plans (Part C) have a high incentive to control costs since the plan is
privately managed. These insurance companies receive a monthly capitation payment to cover
the costs of the member’s care. Any differences in payment between what the government pays
the insurance company and what is paid for the cost of the member’s care is kept as profit.
Therefore, these plans may use stricter controls similar to what the Private insurance plans utilize
including narrow provider networks and prior authorizations before coverage of expensive
therapies (Johnson et al., 2016). The implementation of the ACA has assisted in steadily
increasing the proportion of Medicare eligible patients enrolling into Medicare Advantage plans
which currently amount to 31% of all Medicare patients from 2016 data (Gaba, 2016).

Figure 2: Estimate Total U.S. Healthcare Coverage as of March 2016. This is a pie chart
depicting the breakdown of the various health insurance categories that patients are enrolled with
in the U.S. Employee sponsored plans along with Medicare and Medicaid provide approximately
83% of the healthcare coverage whereas the public exchanges occupy only 4% of the insurance
space (Gaba, 2016; Kotula, 2016).

Estimated Total U.S. Patient Healthcare Coverage
As of March 2016

Employee-Sponsored Insurance (47%)

Medicare (17%)

Off-Exchange Plans (2%)

Uninsured (9%)

Medicaid and CHP (19%)

Public Exchanges (4%)

Other (1%)
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Conclusion
PCSK9 inhibitors are highly effective in lowering LDL-C levels in patients who are
unable to reach their LDL-C goal on statin medication therapy and patients who cannot tolerate
the commonly prescribed first line lipid lowering therapies. Because of their high cumulative
monetary cost and the limited published evidence of clinical efficacy in reducing cardiac events,
PCSK9 inhibitor therapy initiation has often been delayed due to the insurance denial of
coverage. Prior to approving coverage of PCSK9 inhibitors, insurance providers have placed
many restrictions on paying for these medications by requiring an abundance of documentation
to demonstrate the failure of previous therapy (Doshi et al., 2016; Kesselheim et al., 2016).
This is an important area of research because of the very limited data analyzing the
utilization uptake of PCSK9 inhibitor post FDA approval using electronic prescription claims
data. This research study will build upon a single poster presentation from March 2017 to
analyze PCSK9 inhibitor prescription claims data and compare utilization uptake trends between
the three primary payer types. Using claims frequency, the investigators will create a linear
regression to forecast future utilization of PCSK9 inhibitors. Secondly, the investigators will
analyze patient copayment responsibilities between the three payer groups in addition to
copayment card utilization within the Private payer group.
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CHAPTER 3
METHODOLOGY

Research Design
Quantitative archival data analysis of Privately insured, Medicare Advantage, and
Medicaid PCSK9 inhibitor cohorts defined by atorvastatin 80 mg and rosuvastatin 40 mg
utilization (maximum dose high intensity statins).

Specification of Variables
Alirocumab and evolocumab utilization uptake analysis 6-months post FDA approval
compared to maximum dose high intensity statin (atorvastatin 80 mg and rosuvastatin 40 mg)
utilization within each of the three insurance payer groups to adjust for differences between the
population groups. Additionally, copayment amounts were analyzed between payer groups, as
well as manufacturer copayment card utilization within the Private insurance coverage cohort.

Data Sources
The Truven Health Analytics – MarketScan® Research de-identified prescription claims
data set from July 1, 2015 – December 31, 2015 licensed by the Medical University of South
Carolina (MUSC), The College of Health Professions.

Data Set Construction
1. Monthly prescription claims for alirocumab and evolocumab (numerator).
Specific National Drug Code (NDC) numbers included in the data set:
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Alirocumab: 00024590202 (150 mg pen injectors), 00024590402 (150 mg
syringes), 00024590102 (75 mg pen injectors), 00024590302 (75 mg syringes),
00024590101 (75 mg syringes)



Evolocumab: 55513076002 (140 mg Sureclick pen injectors), 55513075001
(140 mg syringes), 55513077001 (420 mg Pushtronic Injectors)

2. July 2015 Atorvastatin 80 mg and rosuvastatin 40 mg claims volume per every 10,000
people (denominator).
3. Prescription claims coverage and cost specifics for alirocumab and evolocumab including
utilization of copayment cards in the form of secondary insurance.

Data Analysis
1. Calculated monthly uptake of PCSK9 inhibitors by insurance payer (Private, Medicare
Advantage, and Medicaid) by comparing claim volume with maximum dose high
intensity statin utilization per 10,000. The claims ratio was used to construct three
different growth curves showing the uptake trends for each PCSK9 inhibitor.
 A future growth curve was constructed based on percentage increases and
compared to an ordinary least squares regression model to forecast utilization for
2016 and beyond.
2. Mean monthly dollar value of patient copayment costs was compared between Medicare
Advantage and Private insurance groups for each PCSK9 inhibitor.
 Percentage of claims with $0 copays per payer categories.
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Private insurance: Percent of claims that have $0 copayments utilizing
manufacturer copayment cards.



Medicare Advantage: Percent of claims with $0 copayments for those
qualifying either for patient assistance programs or those eligible for
Medicare “extra help”.

Institutional Review Board
MarketScan® claims data licensed by MUSC are de-identified and qualify as non-human
research as set forth by the guidelines of the MUSC Institutional Review Board.

Figure 3: Project Conceptualization Chart: A conceptual diagram outlining the study
methodology and data analysis.
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CHAPTER 4
MANUSCRIPT FOR PUBLICATION

Target Journal: Journal of Managed Care and Specialty Pharmacy
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Dear Editor,
I am writing to submit our manuscript entitled “PCSK9 inhibitor Uptake Trends by
Insurance Payers Six Months Post FDA Approval.” The study focuses on Proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors, which have shown superb efficacy in lowing LDL-C
for patients who are not controlled by or are intolerant of first line medication therapy. Because
PCSK9 inhibitors have high yearly costs and, to date, limited clinical data on the reduction of
cardiovascular events due to PCSK9 inhibition, insurance payers have created strict approval
guidelines to manage PCSK9 inhibitor utilization and to control medication spending.
The purpose of this study is to establish whether insurance coverage payer type affects
the rate of utilization uptake of PCSK9 inhibitors. This is an important area of research because
to the author’s knowledge, no large retrospective studies have examined the differences in
utilization uptake of PCSK9 inhibitors among the major payer categories.
To address that research gap, we extracted PCSK9 prescription records from
MarketScan® archival billing data from 2015 for privately insured patients and for patients
covered by Medicaid. We examined uptake over 6 months. Our analysis of PCSK9 inhibitor
claim rates revealed a faster uptake for patients covered by Medicare, compared to the rates
observed for younger, privately insured patients. We identified surprisingly few filled Medicaid
PCSK9 inhibitor claims. The results indicate that, compared to Medicare, commercial insurers
and Medicaid may have stricter approval guidelines to manage PCSK9 inhibitor utilization.
Thank you for considering our manuscript for publication. We appreciate your time and
look forward to your response.

Sincerely,

Kit N. Simpson, DrPH
Professor
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ABSTRACT

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have shown
superb efficacy in lowing LDL-C for patients who are not controlled by or are intolerant of firstline medications such as high intensity statins and ezetimibe. However, because of high yearly
costs along with the life-long cumulative costs for PCSK9 inhibitors, insurance payers have
created strict guidelines to control utilization. This is an important area of research because there
are no large retrospective studies that have examined the differences in utilization uptake of
PCSK9 inhibitors among the major payer categories.

OBJECTIVE: To describe initial uptake of PCSK9 inhibitors and variations in patient payment
by insurance type.

METHODS: Prescription billing data for PCSK9 inhibitor for commercially insured patients,
Medicare beneficiaries with supplemental insurance, and Medicaid patients were extracted from
Truven Health Analytics MarketScan® data for 2015. A patient cohort defined by atorvastatin 80
mg or rosuvastatin 40 mg utilization (maximum dose high intensity statins) served as the
denominator population for uptake rate calculations. Data were limited to the first 6-months post
FDA approval of PCSK9 inhibitors. PCSK9 inhibitor uptake rates were estimated using simple
projection and regression modeling. Out-of-pocket costs were estimated by insurance type.

RESULTS: The results of the claims ratio analysis indicate that the three insurance payer
cohorts had significantly different uptake ratios (P<0.0001) at six months. Initially, the Private
insurance cohort had a faster uptake ratio, but the Medicare cohort ratio surpassed the Private
insurance growth rate by the end of the study. Furthermore, the two forecasting growth curves
(percent increase and ordinary least squares regression) indicate that Medicare has the greater
anticipated future uptake utilization when compared to the Private insurance payer. Using
regression modeling, the uptake slope showed a trend towards greater uptake for Medicare
compared with commercially insured subjects (p=0.0772). Importantly, PCSK9 inhibitor uptake
for the Medicaid cohort was much smaller compared to the commercially insured and Medicare
cohorts.
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CONCLUSIONS: The analysis of PCSK9 inhibitor claims during the first 6 months post FDA
approval revealed a slightly faster uptake trend in Medicare patients compared with patients with
commercial insurance, with uptake for Medicaid patient being much lower. The results indicate
that barriers to access to PCSK9 inhibitors may vary by insurance. Future studies should
examine if barriers are associated with: 1) stricter approval guidelines to manage PCSK9
inhibitor utilization by some insurers; or 2) disparities in prescribing rates associated with
insurance type.

SUMMARY BULLETS

What is already known about this subject


PCSK9 inhibitors have shown superb efficacy in lowing LDL-C for patients not
controlled by or intolerant of first-line medications.



PCSK9 inhibitors have high yearly costs with additive long-term cumulative costs.



Barriers to treatment include insurance coverage ineligibility and high patient copayment
costs.

What this study adds


Estimates differences in uptake rates by payer type for PCSK9 inhibitors during the first
six months after approval.



Describes differences in the out-of-pocket costs for payer groups.



Forecast future utilization of PCSK9 inhibitors using regression modeling.
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INTRODUCTION

The progression of atherosclerotic cardiovascular disease (ASCVD) to myocardial
infarction and ischemic stroke is one of the leading causes of death worldwide 1,2. Risk factors
for developing ASCVD include elevated systolic blood pressure, diabetes, smoking, obesity, and
increased levels of LDL-C 1. Reducing LDL-C has become a target of drug therapy that
primarily utilizes statin medications to lower LDL-C to prevent the formation of atherosclerotic
plaques 3 4 5. Goals for LDL-C reduction vary based on the presence of various cardiovascular
risk factors leading to disease 6. There is significant evidence through meta-analyses showing
that lowering LDL-C with statin therapy reduces the 5-year incidence of major coronary events
and revascularizations 7. Although statins have shown to be very useful in lowering LDL-C,
many patients are not able to tolerate statins due to their debilitating side effects such as
myopathy, rhabdomyolysis, elevated hepatic enzymes, and risk of new-onset diabetes 8. This
significantly impacts quality of life leading to discontinuation of therapy and higher
cardiovascular risks. The primary concern with patients who are not able to tolerate a second
statin is that, until recently, there were no subsequent treatment options to reduce their LDL-C
and their related cardiovascular risk 9,10.
PCKSK9 inhibitors are a new class of specialty medications that have shown superb
efficacy in decreasing LDL-C by up to 60% in patients who are not adequately controlled by
statin therapy alone 11. These medications have the potential for significant utilization, but they
also have the potential for very high economic costs. The two PCSK9 inhibitors currently on the
market are alirocumab (Praluent) approved in July 2015 12 and evolocumab (Repatha)
approved in August 2015 13. They have similar indications as an adjunct to diet and maximally
tolerated statin therapy for treatment of adults with Familial Hypercholesterolemia or ASCVD in
patients who require additional lowering of LDL-C levels. Both are very well tolerated with a
safety profile similar to placebo as shown by two large scale safety studies that reported minimal
drug interaction risks 14. The agents work by inhibiting the binding of the PCSK9 molecule to the
LDL receptor leading to receptor degradation, which allows more LDL receptors to become
available to clear LDL-C from the bloodstream.
While PCSK9 inhibitors have an important role in filling an unmet need in patients
unable to reach their LDL-C goal, the yearly cost of these medications, which can be upwards of
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$14,000, remains highly controversial 15. Once therapy is initiated, patients will potentially
require lifelong maintenance therapy to continue to achieve clinical results, leading to high
cumulative medication costs. The long-term effects on cardiovascular morbidity and mortality
have yet to be fully established, as these medications were approved based on their ability to
lower LDL-C and safety profile 16. Post FDA approval, the GLAGOV trial showed that the
addition of evolocumab to statin therapy resulted in a significantly higher percentage of plaque
regression compared to statin plus placebo, as measured through intravascular ultrasound 17. The
results of the FOURIER study indicate that the evolocumab plus statin group had significantly
reduced total composite outcomes (myocardial infarction, ischemic strokes, or deaths) compared
to patients who received statin plus placebo (5.9% vs. 7.4%, P<0.001). Analyzing the individual
outcomes, there was a reduction of myocardial infarctions, revascularization, ischemic stroke,
and transient ischemic events within the treatment group, but no overall reduction in
cardiovascular death when compared to placebo. 14,18.
Because of these factors, insurance payers have created strict coverage guidelines to
manage utilization and costs. Moreover, differences in the approval criteria between the
insurance payer types (Private, Medicare, and Medicaid) as well as copayment costs may lead to
variations in the rate of utilization uptake of PCSK9 inhibitors among patients, depending on the
type of insurance. This research addresses a significant gap in the literature regarding whether
there are differences in patient access to new, expensive medication treatments by insurance
coverage.

METHODS

An archival data analysis of alirocumab and evolocumab utilization uptake was
performed using de-identified prescription claims data from the 6-month period immediately
following FDA approval for three large insurance payer categories: Private insurance, Medicare,
and Medicaid. We used MarketScan® data (Truven Health Analytics) from July 1, 2015 to
December 31, 2015. These data are de-identified and the study qualify as non-human research.
Prescription claims data for alirocumab and evolocumab were extracted and monthly
uptake rates were calculated using the number of individuals in the data base who received a
maximum dose high intensity statin during July 2015 as the denominator for the rate

33

calculations. Data set construction included quantifying the monthly PCSK9 inhibitor
prescription claims (numerator) and comparing that value to atorvastatin 80 mg and rosuvastatin
40 mg prescription claims per 10,000 in July 2015 (denominator). Each claim for a PCSK9
inhibitor represents a 30-day supply of medication. Any claims for 84-day supply were divided
into their appropriate month to normalize for 28-day fill volumes.
Primary endpoints were PCSK9 growth curves showing the monthly uptake rate trends
for alirocumab and evolocumab combined. Predicted growth curves were constructed as
cumulative percent increases after December 2015. Linear regression prediction of growth by
month, extending the growth trend beyond the last observation was also used to forecast
utilization for 2016 and beyond. Secondary analyses compared the mean monthly patient
copayment costs for the three payer groups. We also examined the percentage of claims with $0
copayments, under the assumption that a $0 copay would be a reasonable proxy measure of
manufacturer copayment card utilization for the private insurance group. The $0 copayment
cases within the Medicare patients were most likely an indication of either use of a patient
assistance program or of a Medicare low income subsidy, since governmental payers are
prohibited from using manufacturer copayment cards by Federal anti-kickback statutes.

RESULTS

Results from the six-month time frame illustrate the monthly claim volumes within each
of the three payer groups as shown in Figure 1. Initial claims were favorable toward alirocumab
since it gained approval a month prior to evolocumab, but evolocumab claim volumes increased
to match alirocumab by December 2015. The raw data indicate that the Private insurance group
had the most claim numbers followed by the Medicare group. The Medicaid group had very few
PCSK9 inhibitor claims; therefore, those data were not included in the growth curve analysis due
to their lack of sufficient prediction power.
A claims ratio comparing claim volume to maximum dose high intensity statin utilization
per 10,000 for each payer type was used to construct growth curves showing the uptake trends
for each PCSK9 inhibitor. Due to the limited number of claims, monthly claim numbers for both
alirocumab and evolocumab were combined within each payer group when creating the
comparison ratio in Table 1. The results of the claims ratio curves indicate that while the Private
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insurance uptake ratio had faster initial growth curves in August and September, the Medicare
growth ratio surpassed the Private insurance growth rate by November and December. Data
analysis using the Chi -Square indicates statistically significant differences between the three
populations (P<0.0001).
Two forecasting growth charts were constructed to predict future uptake growth for the
Medicare and Private insurance groups. The first growth chart was constructed using a fixed
percentage increase each month based on the percent observed from November to December
2015 (Figure 2). The second growth curve used ordinary least squares regression modeling by
month, extended for 18 months past the last data point to illustrate the observed trajectory
(Figure 3). Both growth curves indicate that the Medicare cohort had the greater uptake
utilization when compared to the Private insurance payer cohort. Furthermore, the regression
slope estimate (p=0.0772) showed a statistical trend toward greater uptake for the Medicare
cohort.
Secondary measures focused on patient copayment analysis. Both Medicare and Private
insurance had a similar total percentage of patients taking PCSK9 inhibitors with $0 copayments
(44%) as shown in Table 2. Prescriptions that were filled for more than a 28-day supply were
standardized to reflect a copayment for a 28-day supply. Evolocumab Medicare claims had the
highest mean copayment amount of $163.56 per month versus the alirocumab Medicare mean of
$63.67, which was the lowest copayment amount. Private insurance claims had mean
copayments of $78 and $98 per month for evolocumab and alirocumab, respectively (Table 2).

DISCUSSION

Alirocumab and evolocumab are currently the only two PCSK9 inhibitor medications
approved by the FDA. They have similar mechanisms of action, effectiveness, and costs. The
primary focus of this study was to evaluate whether there were any differences in uptake
utilization among insurance payer groups for PCSK9 inhibitors during the first six-months after
their approval by the FDA.
We used maximum dose high intensity statin claim volumes from July 2015 as the
denominator for the rate calculation. This approach allowed us to normalize the differences
between the populations included in each data set and calculate an uptake rate based on the size
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of the potentially eligible population within each insurance cohort. Statistical analysis showed
that each of the three insurance payer groups had significantly different uptake ratios (p<0.0001).
When comparing PCSK9 inhibitor claims uptake ratios between the Medicare population and the
Private Insurance population, Medicare had a faster uptake trajectory in both the fixed
percentage increase estimation approach and in the regression modeling approach, although the
Private insurance cohort had higher raw claim numbers. Furthermore, the regression modeling
curve suggests a trend in the Medicare cohort toward greater future uptake. This potential trend
toward greater uptake could be due to various effects, including: 1) less stringent insurance
approval guidelines compared to the private insurance, which would allow for faster approval; 2)
this population having more advanced cardiac markers that make it easier to meet approval
criteria; or 3) differences in practice patterns and/or amount of care provided by cardiology
specialists who may be “early adopters” of new drugs.
The uptake for the Medicaid cohort was most surprising, this group had the lowest
numbers of PCSK9 inhibitor claims during this time period. This is surprising given the
Medicaid expansion legislated through the Affordable Care Act that was progressing in 2015.
While the uptake rate was very different for the Medicaid group, the underlying population of
“potentially eligible” patients (defined by patients receiving high intensity statin claim volumes
during July 2015) were very similar for the Medicaid and Medicare cohorts. A possible reason
for the low number of Medicaid PCSK9 inhibitor claims could be due to local Medicaid approval
criteria being slow to change with many states in the data set having restrictions in place for high
cost medication coverage 19.
The analysis of co-payment patterns indicated that the $0 copayment percentages were
similar between the Medicare and Private insurance cohorts. An important difference between
Private insurance and Medicare is that manufacturer copayment cards cannot be used to cover
Medicare copayments costs due to federal anti-kickback laws (42 U.S.C. 1320a–7b). This creates
a predicament for Medicare patients because they may have higher copayments, while Private
insurance plans allow for manufacturer sponsored copayment cards to reduce out-of-pocket costs
to negligible levels 20,21. However, the Federal government allows pharmaceutical manufacturers
to donate drugs to patient assistance programs as “independent” charities, this mechanism might
have been the reason for similar rates of $0 copayments. If this is the case, then the $0
copayment proportion for PCSK9 inhibitors may be expected to decrease as the demands for the
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drugs increase and patient assistance program waiting lists for copayment relief for Medicare
patients gets longer.
It appears that a possible underutilization of manufacturer copayment cards may be
present for the privately insured patients. We observed that 65% of patients were paying out-ofpocket costs that were much higher than expected if copayment cards were used. This could be
because the readily available manufacturer educational materials were not provided to patients at
the initiation of therapy, or patients are not informed about manufacturer copayment cards when
getting their prescriptions filled at the point of service.
This study has a number of limitations. The primary limitation was the short timeframe of
data availability at the time of the investigation, leading to a small number of observations for
analysis. A small number makes it difficult to compare subtle differences between populations or
to forecast future growth curves. In addition, the Medicare patients who have supplementary
insurance constitute only a small percent of all Medicare patients, and may be different from
Medicare patients with Part D prescription coverage. Lastly, prescription billing data bases rely
on the accuracy of data entered at the point of service when prescriptions are dispensed. We
relied heavily on the “day supply” variable, if this variable is inaccurate our measure of fill
behavior will be inconsistent.
Important questions about PCSK9 uptake and use are needed in the future. Once 2016
PCSK9 inhibitor claims data become available, we must examine several issues: 1) do the early
trends that we observed continue? 2) When do uptake rates begin to level out? 2) Was the low
uptake observed for Medicaid simply a slow start, or are there consistent disparities in access to
PCSK9 inhibitors for these beneficiaries? Do we see drop outs and switching behavior? If so, is
this associated with the copay burden placed on the patient? Finally, the most essential research
question will be: when do we begin to see the improved health benefits that we expect for
patients now getting PCSK9 inhibitors.

CONCLUSION

The purpose of this study was to examine whether insurance type affected the rate of
utilization uptake of PCSK9 inhibitors in the first six months after FDA approval of this new
class of medications. This analysis of PCSK9 inhibitor claims revealed a trend of higher uptake
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for Medicare patients, when compared to Private and Medicaid insurance cohorts. The results of
this small early study indicate the need to monitor uptake rates and access differences for PCSK9
inhibitors. It is important be vigilant to avoid the creation of disparities in access due to
unintended “rationing” consequences of approval guidelines for PCSK9 inhibitors. Examination
of patient out-of-pocket costs shows similar percentages of $0 copays for Medicare and Private
insurance payers. However, fifty-six percent of Private insurance patients were not utilizing
manufacturer copayment cards to lower their out-of-pocket costs and therefore paying more for
their prescriptions than needed. This group may be a high risk of discontinuation of an important,
potentially lifesaving drug, because of gaps and failures in our education or dispensing systems.

38

Figure 1: Bar chart depiction of PCSK9i claims data divided into payer groups. Private
insurance had the highest raw numbers while Medicaid claims were very limited despite having
an underlying statin claims population size comparable to Medicare.
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Table 1: Monthly PCSK9 inhibitor prescription claims and Uptake Rates per 10,000
(denominator population is number of individuals receiving atorvastatin 80 mg or rosuvastatin 40
mg in July in the insured group).
2015

Medicare:

July

August

September

October

November

December

July 2015 atorvastatin 80mg and rosuvastatin 40 mg claims: 20,272

Evolocumab

0

0

2

17

58

115

Alirocumab

0

9

20

57

70

91

0.00

4.44

10.85

36.50

63.14

101.62

Rate per 10,000
(Combined)

Private Payer:

July 2015 atorvastatin 80mg and rosuvastatin 40 mg claims: 50,370

Evolocumab

0

0

14

35

83

191

Alirocumab

0

54

113

151

180

219

0.00

10.72

25.21

36.93

52.21

81.40

Rate per 10,000
(combined)

Medicaid:

July 2015 atorvastatin 80mg and rosuvastatin 40 mg claims: 18,344

Evolocumab

0

0

0

3

6

8

Alirocumab

0

0

0

5

5

6

0.00

0.00

0.00

1.59

2.18

2.78

Rate per 10,000
(combined)
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Figure 2: Predicted future growth curve based on PCSK9i claims percent increase from
November to December 2015. Populations were adjusted based on atorvastatin 80 mg and
rosuvastatin 40 mg claims volume in July 2015. Claims growth curve forecasted through
December 2016. Growth curves indicate a greater increase in the Medicare population compared
to the Private insurance. Medicaid claims were too small to include in the forecasting calculation.
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Figure 3: Predicted future growth curve based on an Ordinary Least Squares Regression
analysis. Claims growth curve forecasted through July 2017. Populations were adjusted based on
atorvastatin 80 mg and rosuvastatin 40 mg claims volume in July 2015. Growth curves and the
Medicare slope indicate a trend toward having significance when compared with the Private
insurance growth curve. Medicaid claims were too small to include in the forecasting calculation.
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Table 2: Secondary measure results comparing patient copayment costs between Medicare and
Private Insurance: Percent of claims having no copayments, mean monthly dollar value of patient
copayment costs, minimum and maximum dollar amount paid for each 28-day medication
supply.
Percent with $0
Copay

Mean Monthly
Copay

Minimum
Copay

Maximum
Copay

Medicare
Evolocumab

37.30%

$163.55

$3.59

$1114.32

Alirocumab

49.77%

$63.67

$3.33

$492.98

Combined

44.06%

Private Payer
Evolocumab

32.78%

$77.95

$5

$1156.67

Alirocumab

49.44%

$98.08

$5

$1154.48

Combined

44.03%
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APPENDIX
Table 3: The Truven Health Analytics – MarketScan® Research de-identified prescription claims data set codes licensed by the
Medical University of South Carolina, The College of Health Professions
NDCNUM

STRNGTH

GENNME

SEQNUM

VERSION

ENROLID

SVCDATE

YEAR

AGE

AWP

COB

COINS
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COPAY

DAYSUPP

DEDUCT

DISPFEE

GENERID

INGCOST

METQTY

NETPAY

PAY

QTY

REFILL

Table 4: Summary of Clinical Trials: Key Demographic Populations for Evaluating Efficacy and Side Effects

Population

Alirocumab Trials

Evolocumab Trials

Monotherapy



ODYSSEY MONO (n=103)  24 weeks



MENDEL-2 (n=614)  12 weeks

Combination Therapy






ODYSSEY OPTIONS I (n=355)  24 weeks
ODYSSEY OPTIONS II (n=305)  24 weeks
ODYSSEY COMBO I (n=316)  52 weeks
ODYSSEY COMBO II (n=720)  104 weeks



LAPLACE -2 (n=1899)  12 weeks

HeFH





ODYSSEY FH I (n=486)  78 weeks
ODYSSEY FH II (n=249)  78 weeks
ODYSSEY High FH (n=107)  78 weeks



RUTHERFORD-2 (n=331)  12 weeks




TESLA (n=50)  12 weeks
TAUSSIG (n=100)  12 weeks

HoFH
Statin Intolerant



ODYSSEY ALTERNATIVE (n=314) 24 weeks




GAUSS-2 (n=307)  12 weeks
GAUSS-3 (n=218)  24 weeks

Long-term Safety and
Efficacy



ODYSSEY LONGTERM (n=2341)  78 weeks



DESCARTES (n=905)  52 weeks

Long term open label
extension



OSLER-2 (n=3141) 104 weeks

Coronary
atherosclerosis Imaging



GLAGOV (n=986)  78 weeks



FOURIER (n=27,564)  2.2 years



EBBINGHAUS (n=1974)  19 months

Secondary Prevention



ODYSSEY OUTCOMES, Completion date 12/2017
("Odyssey outcomes: Evaluation of cardiovascular outcomes after an
acute coronary syndrome during treatment with alirocumab,")

Cognitive Function
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Table 5: An overview of relevant clinical trials that led to FDA approval of Alirocumab, based on a review of studies by
Gouni-Berthold et al. (2016).
The table highlights study design descriptions as well as the number of patients enrolled and duration of treatment. Each study showed
a significant decrease in LDL-C with alirocumab when compared to the control group (placebo, statin and / or ezetimibe). To date, no
published studies with alirocumab have linked its LDL-C lowering abilities to clinical decreases in cardiac events. A long term clinical
evaluation of the effectiveness of alirocumab in reducing cardiac events is anticipated to be published in 2018.

Study name

PCSK9i Dose

Patients

ODYSSEY
MONO
(Roth et al.,
2014)

(1) Alirocumab
75 mg Q2W

103
(1:1)

ODYSSEY
OPTIONS I
(Bays et al.,
2015)

(1) Add-on
alirocumab 75
mg Q2W

Dose increased
to 150 mg
Q2W at week
12 if LDL was
> 70 mg/dL

Dose increased
to 150 mg
Q2W at week
12 if LDL
target not met
on week 8

355
(1:1:1:1)

Patient
Type

Design

Control

LDL 100190 mg/dL
and
moderate
CV risk

Multicenter,
randomized,
double blind,
double dummy,
active
controlled

(2) ezetimibe 10 mg/day

CV risk

Multicenter,
randomized,
double blind,
double dummy,
parallel group.

(2) ezetimibe 10 mg/day;

Primary:
LDL 70
Secondary:
LDL 100

Concomitant
treatment
None

DOT

24 Weeks

Outcomes
(Reduction in LDL)
Mean at week 24 (1) 47.2% vs
(2) ezetimibe 15.6%
(P<0.0001)

Adverse Events

Discontinuation of
therapy:
(1) 9.6% treatment
(2) 7.8% Ezetimibe.

(3) Doubling atorvastatin
dose
20 mg/day40mg/day
40mg/day80mg/day;
(4)
switching atorvastatin 40
mg/day  rosuvastatin
40 mg/day

Baseline
statins:
atorvastatin 20
mg = 47.6%
atorvastatin 40
mg = 52.4%

24 Weeks

(1) Adding alirocumab to
atorvastatin 20 mg and 40 mg
-44.1% and 54% (P<0.001);
(2) Adding ezetimibe20.5% and 22.6%;
(3) Doubling atorvastatin dose
-5% and 4.8%;
(4) Switching to rosuvastatin 21.4%
86% of patients remained on
alirocumab 75 mg dose.
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Discontinuation of
therapy:
(1) alirocumab: 7%;
(2) ezetimibe: 4%;
(3) dbl atorvastatin 8%
(4) rosuvastatin
switch:8%

ODYSSEY
OPTIONS II
(Farnier et al.,
2016)

(1) Add on
alirocumab 75
mg Q2W

305
(1:1:1)

CV risk
Primary:
LDL 70

Dose increased
to 150 mg
Q2W at week
12 if LDL
target not met

Double-blind,
Double
dummy,
Randomized,
Phase 3 study

(2) Adding ezetimibe 10
mg/day or

Baseline
statins:

(3) doubling the dose of
rosuvastatin

Rosuvastatin
10 mg=47.5%

Secondary:
LDL 100

24 Weeks

rosuvastatin 20
mg=52.4%

Rosuvastatin 10 mg group:
(1) add-on alirocumab 50.6%
(2) ezetimibe 14.4%
(3) doubling rosuvastatin
16.3% (P<0.0001)

Discontinuation of
therapy:
(1) alirocumab: 5%;
(2) ezetimibe: 8%;
(3) doubling rosuvastatin
dose:5%

Rosuvastatin 20 mg group:
(1) add-on alirocumab 36.6%
(2) ezetimibe 11%
(3) doubling rosuvastatin
15.9% (P= 0.0136 and 0.0453
with a threshold of P<0.0125)
80% of patients remained on
alirocumab 75mg dose

ODYSSEY
ALT
(Moriarty et
al., 2014;
Moriarty et
al., 2015)

ODYSSEY
COMBO I
(Kereiakes et
al., 2015)

(1) Alirocumab
75 mg Q2W

314
(2:2:1)

Dose increased
to 150 mg
Q2W at week
12 depending
on week 8
LDL

(1) Add-on
alirocumab 75
mg Q2W,
Dose increased
to 150 mg
Q2W at week
12 if LDL was
> 70 mg/dL on
week 8

CV risk
with statin
intolerance

Multicenter,
randomized,
double blind,
double dummy

Primary:
LDL 70

Placebo,
(2) ezetimibe 10 mg/day,
or
(3) atorvastatin 20
mg/day

None

24 Weeks

At Week 24(1) alirocumab 45.0% vs
(2) ezetimibe 14.6%
(P<0.0001). Atorvastatin data
was not reported

Injection site reactions:
(1) alirocumab 4.8%, (2)
ezetimibe 4.8%
(3) atorvastatin 1.6%

Secondary:
LDL 100

316
(2:1)

CV risk
Primary:
LDL 70

Discontinuation of
therapy:
(1) alirocumab18.3%
(2) ezetimibe 25%
(3) atorvastatin 25.4%

Multicenter,
randomized
placebo
controlled

(2) Placebo

Maximally
tolerated statin
therapy

52 Weeks

At week 24:
(1) alirocumab 48.2% vs
(2) placebo 2.3% (P<0.0001)
with reductions remaining
through week 52.

Discontinuation of
therapy:
(1) 6.3% treatment
(2) 7.5 % placebo.
Injection site reactions
(1) 5.3% treatment
(2) 2.8% placebo

Secondary:
LDL 100
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ODYSSEY
COMBO II
(Cannon et
al., 2015)

(1) Add-on
alirocumab 75
mg Q2W vs.
Ezetimibe

720 (2:1)

Primary:
LDL 70

Dose increased
to 150 mg
Q2W at week
12 if LDL was
> 70 mg/dL on
week 8

ODYSSEY
FH I
(Kastelein et
al., 2015)

(1) Add-on
alirocumab 75
mg Q2W

(1) Add-on
alirocumab 75
mg Q2W

486 (2:1)

(1) Add-on
alirocumab 150
mg Q2W

HeFH
Primary:
LDL 70

(2) Ezetimibe 10 mg/day

Maximally
tolerated statin
therapy

104 Weeks

At week 24:
(1) alirocumab 50.6% vs
(2) ezetimibe 20.7%
(P<0.0001) with reductions
remaining through week 52.

Discontinuation of
therapy:
(1) 7.5% alirocumab
(2) 5.4% ezetimibe

Multicenter,
randomized,
double blind

(2) Placebo

All patients
receiving high
dose statin
therapy

78 Weeks

At week 24,
difference between treatment
and placebo:
-57.9% (P<0.0001) with
reductions remaining through
week 78

Discontinuation of
therapy:
(1) 3.4% alirocumab
(2) 6.1% placebo

At week 24, difference
between treatment and
placebo:
-51.4% (P<0.0001) with
reductions remaining through
week 78.

Discontinuation of
therapy:
(1) 3.6% alirocumab
(2) 1.2 % placebo.

At week 24
(1) Alirocumab -45.7% vs
(2) placebo 6.6% (P<0.0001)
with reductions remaining
through week 78.

Discontinuation of
therapy:
(1) 4.2% alirocumab
(2) 5.7 % placebo.

Secondary:
LDL 100

249 (2:1)

HeFH
Primary:
LDL 70

-Dose
increased to
150 mg Q2W
at week 12 if
LDL was > 70
mg/dL on week
8
ODYSSEY
HIGH FH
(Ginsberg et
al., 2016)

Multicenter,
randomized,
double blind,
double dummy,
active
controlled

Secondary:
LDL 100

Dose increased
to 150 mg
Q2W at week
12 if LDL was
> 70 mg/dL on
week 8
ODYSSEY
FH II
(Kastelein et
al., 2015)

High CV
risk

Multicenter,
randomized,
double blind

(2) Placebo

All patients
receiving high
dose statin
therapy

78 Weeks

Secondary:
LDL 100

107 (2:1)

HeFH
LDL 160

Multicenter,
randomized,
double blind

(2) Placebo

Maximally
tolerated statin
therapy

78 Weeks

Injection site reactions
(1) 12.4% alirocumab
(2) 11.0% placebo

Injection site reactions
(1)11.4% alirocumab
(2) 7.4 % placebo

Injection site reactions
(1) 8.3% alirocumab
(2) 5.7 % placebo
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ODYSSEY
LONGTERM

(Robinson et
al., 2015)

(1) Add- on
alirocumab 150
mg Q2W

2341
(2:1)

HeFH or
established
CV disease.

Multicenter,
randomized,
double blind

(2) Placebo

Maximally
tolerated statin
therapy

78 Weeks

LDL 70

At week 24
(1) alirocumab 61% vs
(2) placebo 0.8% (P<0.0001)
with reductions remaining
through week 78.

Discontinuation of
therapy:
(1) 7.2% alirocumab
(2) 5.8 % placebo.
Injection site reactions
(1) 5.9% alirocumab
(2) 4.2% placebo

ODYSSEY

5-year trial
evaluating
the clinical
efficacy in
reducing
cardiac
events
*Clinicaltrials.gov (Accessed 8/16/2017)

OUTCOMES*

Multicenter,
randomized
placebo
controlled

(2) Placebo

60 Months

52

Ongoing: Completion date
estimated December 2017

Evaluating time to CV
event

Table 6: An overview of relevant clinical trials that led to FDA approval and indication expansion, based on review of studies
by Gouni-Berthold et al. (2016) .
The table highlights study design, number of patients enrolled, and duration of treatment. Each study showed a significant decrease in
LDL-C with evolocumab when compared to the control group. There were no significant differences in the side effect profiles
between the groups. More recent studies have evaluated evolocumab’s clinical efficacy in linking LDL-C reduction to a reduction in
clinical cardiac events. Based on coronary imaging, the GLAGOV study shows a significant regression in atherosclerotic plaque in the
evolocumab group compared to control. The FOURIER study is the first showing a significant decrease in the primary cardiac
endpoints associated with evolocumab’s LDL-C lowering ability. Also, the EBBINGHAUS study showed that significantly lowering
LDL-C does not significantly influence a patient’s cognitive function.

Study name
MENDEL-2
(Koren et al.,
2014)

PCSK9i
Dose
(5) PO
placebo +
Evolocumab
140 mg Q2W

N

Patient
Type

614
(1:1:1:
1:2:2)

LDL >100
and low CV
risk

Design

Control

Randomized,
double-blind,
placebocontrolled,
phase 3

(1) PO placebo + SC
placebo Q2W
(2) PO placebo + SC
placebo monthly
(3) ezetimibe + SC
placebo Q2W
(4) ezetimibe + SC
placebo monthly

(6) PO
placebo +
Evolocumab
420 mg
monthly

LAPLACE-2
(Robinson et al.,
2014)

Add-on
Evolocumab
140 mg SC
Q2W
Add-on
Evolocumab
420 mg SC
Q4W

1,899
(2:2:1:1)

Primary
HCL and
mixed
dyslipidemia
on
background
intensive or
moderate
statin +/ezetimibe

Randomized

Placebo SC Q2W

Concomitant
treatment

DOT

none

12 Weeks

Atorvastatin
80 mg

12 weeks

Outcomes
(Reduction in LDL)
At Week 12, % change from
baseline
(1) +0.1
(2) -1.3
(3)-17.8
(4)-18.6
(5)-57.0 (P<0.001)
(6)-56.1 (P<0.001)

Mean Change in baseline
Q2W and Q4W regimens:

Placebo SC Q4W
Rosuvastatin
40 mg

Atorvastatin 80 mg + Eva
(-76.3% and -70.5%)

Simvastatin 40
mg

Rosuvastatin 40 mg + Eva
(-68.3% and -55.0%)
Simvastatin 40 mg + Eva
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Adverse Events
Discontinuation
(1) 3 (4%)
(2) 3 (4%)
(3) 4 (5%)
(4) 1 (1%)
(5) 4 (3%)
(6) 3 (2%)
Injection site reaction:
(1) 2 (3%)
(2) 6 (8%)
(3) 4 (5%)
(4) 3 (4%)
(5) 10 (7%)
(6) 6 (4%)
Discontinuation of
therapy:
(1) 1.9% Eva
(2) 2.2 % placebo.
Injection site reactions
(1) 1.3% Eva
(2) 1.4 % placebo

(-70.6% and -60.4%)
RUTHERFORD2

(Raal, Stein, et
al., 2015)

Evolocumab
140 mg SC
Q2W

331 (2:1)

HeFH

Randomized,
double blind,
placebo
controlled

Placebo Q2W

Maximally
tolerated statin
therapy

Placebo Q4 W

12 weeks

Evolocumab: -61.3%
Placebo: -2.0% (P<0.0001)

Evolocumab
420 mg SC
Q4W
TESLA Part B
(Raal,
Honarpour, et
al., 2015)

TAUSSIG
(Raal et al.,
2017)

GAUSS-2
(Stroes et al.,
2014)

Evolocumab
420 mg

Evolocumab
420 mg
monthly
(every 2
weeks if on
apheresis
n=34)
Dosing
increased to
every 2
weeks after
12 weeks in
patients not
on apheresis
Evolocumab
140 mg Q2W
with placebo
Q2W or
Q4W

Q2W Regimen:

Q4W Regimen:

50 (2:1)

100

HoFH

HoFH, some
receiving lipid
apheresis

Randomized,
double blind,
placebo
controlled

Single arm,
Open-label

Placebo

Maximally
tolerated statin
therapy

None

Apheresis

12 weeks

48 weeks

Evolocumab: -55.7%
Placebo: -5.5% (P<0.0001)
Evolocumab: -23.1%
Placebo: -7.9% (P<0.0001)

Week 12: -20.9%
Week 24: -23.4%
Week 48: -18.6%

Discontinuation of
therapy:
(1) 0% Eva
(2) 0% placebo.
Injection site reactions:
(1) 5-7% Eva
(2) 4% placebo
Discontinuation of
therapy:
(1) 0% Eva
(2) 0% placebo.
Injection site reactions:
(1) 0% Eva
(2) 6% placebo
Discontinuation of
therapy:
(1) 3% Evo
(2) 0% Apheresis
Injection site reactions:
(1) 4% Evo
(2) 29% Apheresis

307
(2:2:1:1)

Statin
intolerance

Randomized,
double blind,
placebo and
ezetimibe
controlled

Ezetimibe 10 mg QD

Evolocumab
420 mg Q4W
with placebo

54

33% taking lipid
lowering
therapy

12 weeks

(1) Ezetimibe + placebo
Q2W:
-19.2%
(2) Evolocumab Q2W +
placebo QD: -56.1%

Discontinuation of
therapy:
(1): 8%
(2): 6%
(3):18%
(4): 11%

(3) Ezetimibe QD + placebo
Q4W:
-16.6%

Injection site reactions:
(1): 2%
(2): 3%

Q2W or
Q4W

(4) Evolocumab Q4W +
placebo QD: -55.3%

(3): 14%
(4): 3%

P<0.001
GAUSS-3
(Nissen, DentAcosta, et al.,
2016; Nissen,
Stroes, et al.,
2016)

Evolocumab
420 mg Q4W
+ placebo PO

DESCARTES
(Blom et al.,
2014)

Add-on
Evolocumab
420 mg
monthly

Phase B:
218 (2:1)

Statin
intolerance

Randomized,
double blind,
placebo and
ezetimibe
controlled

Placebo SC +
ezetimibe PO

none

905
(2:1)

Evolocumab
140 mg Q2W

3141
(2:1)

or

GLAGOV
(Nicholls et al.,
2016; Puri et al.,
2016)

Ezetimibe: -16%
Evolocumab: -52.8%
P<0.001

Discontinuation of SC
therapy:
(1) 4.8% Evo
(2) 5.5% Ezetimibe
Injection site reactions:
(1) 4.8% Evo
(2) 2.7% Ezetimibe

LDL >75
mg/dL,
FG 400
mg/dL

Randomized,
double-blind,
placebocontrolled,
phase 3

Placebo

Long term
open label
extension

Randomized
open labelcontrolled
extension

Standard therapy

Coronary
atherosclerosis
imaging

Randomized,
double-blind,
placebocontrolled

Placebo

Various levels
of CV risk

OSLER-2
(Sabatine et al.,
2015)

24 weeks

Evolocumab
420 mg Q4W
Evolocumab
420 mg Q4W

968
(1:1)

(1) diet alone
(2) atorvastatin
10 mg
(3) atorvastatin
80 mg
(4)
combination
atorvastatin 80
mg and
ezetimibe 10 mg

52 Weeks

Statins and/or
ezetimibe

48 weeks

(1) 55.7% diet alone
(2) 61.6% atorvastatin 10 mg
(3) 56.8% atorvastatin 80 mg
(4) 48.5% combination
atorvastatin 80 mg and
ezetimibe 10 mg
(P<0.001)

Discontinuation:
Evolocumab: 2.2%
Placebo: 1.0%

LDL reduction in
evolocumab group: -64%

Data not reported
separately

Injection site reaction:
Evolocumab: 2.7%
Placebo: 2.0%

(P<0.001)

Stable statin
therapy > 4
weeks

78 weeks

Evolocumab had a mean
decrease in LDL by 56.5
mg/dL (P<0.001)
Evolocumab had a greater
percentage of plaque
regression compared to
placebo: 64.3% vs 47.3%
(P<0.001)
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Injection site reaction:
Evolocumab: 0.4%
Placebo: 0%

FOURIER
(Sabatine et al.,
2017)

Evolocumab
140 mg Q2W

27,564

or

Secondary
cardiac
prevention

Randomized,
double-blind,
placebocontrolled

Placebo

Statin therapy
and / or
ezetimibe

2.2 years

Evolocumab
420 mg Q4W

Evolocumab had a 59%
reduction in LDL
compared with placebo
(P<0.001)
Primary cardiac endpoints:
Evolocumab vs placebo
9.8% vs 11.3 % (P<0.001)
Secondary cardiac
endpoints:
Evolocumab vs placebo
5.9% vs7.4% (P<0.001)

EBBINGHAUS
(R. P.
Giugliano,
Mach, Zavitz,
Kurtz, Im, et al.,
2017)

Evolocumab
140 mg Q2W
or
Evolocumab
420 mg Q4W

1974

Assessment
of Cognition
function

Open label
extension of
the
FOURIER
study (a
placebocontrolled
trial of EV
added to
statin
therapy)

Placebo

Statin therapy
and / or
ezetimibe

56

19
months

Change in baseline for
working memory strategy
index of executive function
was not significantly
different (P<0.001)
between groups. Secondary
endpoints for working
memory, episodic memory,
psychomotor speed was
not significantly different.
No association between
LDL-C levels and
cognitive changes.

Injection site reaction:
Evolocumab: 2.1%
Placebo: 1.6%
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